C4 Therapeutics (CCCC) Change in Acquisitions & Divestments (2019 - 2026)

C4 Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $57.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 4.13% year-over-year to $57.0 million in Q1 2026; TTM through Mar 2026 was $221.3 million, a 5.26% decrease from a year earlier, with the FY2025 full-year figure at $219.1 million, down 6.07% from the prior year.
• Change in Acquisitions & Divestments climbed to $57.0 million in Q1 2026 per CCCC's latest filing, from $52.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $90.3 million in Q3 2023 and bottomed at $51.2 million in Q3 2025.
• The 5-year median for Change in Acquisitions & Divestments is $64.2 million (2023), against an average of $63.7 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 44.85% in 2022; the steepest drop was 37.05% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at $67.1 million in 2022, then climbed by 4.35% to $70.0 million in 2023, then retreated by 22.19% to $54.4 million in 2024, then dropped by 3.86% to $52.3 million in 2025, then increased by 8.94% to $57.0 million in 2026.
• Per Business Quant, the three latest CCCC Change in Acquisitions & Divestments figures stand at $57.0 million (Q1 2026), $52.3 million (Q4 2025), and $51.2 million (Q3 2025).